Battling Arthritis

According to results of research presented today at EULAR 2008 (the Annual European Congress of Rheumatology in Paris, France), adalimumab therapy is effective and well-tolerated in ankylosing spondylitis (AS), rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients with a previously inadequate response to anti-tumour necrosis factor (anti-TNF) therapies etanercept and infliximab.

This positive response to adalimumab was greatest for patients who had been intolerant of their anti-TNF therapies, or had lost their initial responses, compared with those who had had no response to prior anti-TNF therapies at all.

More →

Share This

First it was Roche’s Actimra, now it is Abbott’s Humira that’s been approved in Japan.

The Japanese Ministry of Health, Labour and Welfare has approved Humira for the treatment of rheumatoid arthritis (RA) in patients with inadequate response to conventional therapy.

“The approval of HUMIRA in Japan is a significant milestone for Abbott,” said Glenn Warner, vice president, Pharmaceuticals, Japan, Abbott. “This approval is both good news for Japanese patients and a significant step forward for Abbott in Japan.”

More →

Share This